Collaborations
The ubiquitin proteasome system contains a plethora of novel therapeutic targets. Progenra’s ability to discover novel UPS modulators, Molecular Glues and PROTACs employing its drug discovery platform has created several opportunities for establishing partnerships and collaborations with companies as well as academic institutions.
Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential. We are pleased to have collaborations with several leading national and international academic institutions, including:
Baylor College of Medicine
Cedar Sinai Medical Center
Children’s Hospital of Philadelphia
Chinese Academy of Sciences
Curie Institute Paris
Emory University
Harvard University Dana-Farber Cancer Institute
Johns Hopkins Medical School
Johns Hopkins University School of Medicine
Karolinska Institute
Mt Sinai Medical School, NY
National Cancer Institute, NIH
National Institute of Allergy and Infectious Diseases, Pl
University of Alabama at Birmingham
University of Michigan Medical Center
University of Michigan Medical School
University of Oxford
University of Pennsylvania School of Medicine
University of Pittsburgh
University of Texas M D Anderson Cancer Center
University of Toronto
